Abstract Rivaroxaban, an inhibitor of Factor Xa, is a direct oral anti-coagulant that has been found to be noninferior to warfarin in preventing cerebral ischemia in patients with non-valvular atrial fibrillation and in the subgroup of patients with a history of the previous stroke or transient ischemic attack. Vascular neurologists in daily clinical practice may encounter patients taking rivaroxaban or patients who may benefit from its use. In this paper, we review the current clinical indications, contraindications, and clinical management guidelines for rivaroxaban while providing a special focus on neurological aspects and expert opinions on rivaroxaban therapy management in various situations that a neurologist may encounter when treating patients with an ischemic stroke (including those requiring intravenous or intra-arterial reperfusion therapy) and patients with an intracerebral hemorrhage. Since data from clinical trials and real-life data are missing in some clinical situations, strong recommendations are not always available. Nevertheless, practical guidelines should be adopted to maximize benefits from this oral anti-coagulant
Use of rivaroxaban in patients with stroke / Toni, Danilo; Carolei, Antonio; Caso, Valeria; Consoli, Domenico; Del Sette, Massimo; Inzitari, Domenico; Melis, Maurizio; Micieli, Giuseppe; Provinciali, Leandro; Ricci, Stefano; Santalucia, Paola; Toso, Vito. - In: NEUROLOGICAL SCIENCES. - ISSN 1590-1874. - STAMPA. - 38:5(2017), pp. 745-754. [10.1007/s10072-017-2855-3]
Use of rivaroxaban in patients with stroke
Toni, Danilo;
2017
Abstract
Abstract Rivaroxaban, an inhibitor of Factor Xa, is a direct oral anti-coagulant that has been found to be noninferior to warfarin in preventing cerebral ischemia in patients with non-valvular atrial fibrillation and in the subgroup of patients with a history of the previous stroke or transient ischemic attack. Vascular neurologists in daily clinical practice may encounter patients taking rivaroxaban or patients who may benefit from its use. In this paper, we review the current clinical indications, contraindications, and clinical management guidelines for rivaroxaban while providing a special focus on neurological aspects and expert opinions on rivaroxaban therapy management in various situations that a neurologist may encounter when treating patients with an ischemic stroke (including those requiring intravenous or intra-arterial reperfusion therapy) and patients with an intracerebral hemorrhage. Since data from clinical trials and real-life data are missing in some clinical situations, strong recommendations are not always available. Nevertheless, practical guidelines should be adopted to maximize benefits from this oral anti-coagulantFile | Dimensione | Formato | |
---|---|---|---|
Toni_Use of rivaroxaban_2017.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
466.11 kB
Formato
Adobe PDF
|
466.11 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.